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1098-612X/10/100802+05 $36.00/0Staphylococci and enterococci are common causes of urinary tract infections in
cats. However, both species are rarely implicated together as causes of lower
urinary tract infections associated with urethral obstruction. This report
describes the first case of a multi-drug methicillin-resistant Staphylococcus
pseudintermedius belonging to spa type t06 and Enterococcus faecalis urinary
infection in a cat with pre-existing and recurrent urethral obstruction. Both
species were isolated at >105 CFU/ml from a cystocentesis urine specimen.
Clinical and ultrasound features, results from urinalysis, urine culture,
molecular typing and susceptibility testing by minimal inhibitory concentrations
determination are described. Oral treatment with nitrofurantoin, the only
antimicrobial agent that constituted a viable therapeutic option, had a positive
outcome.Date accepted: 16 April 2010  2010 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.A
5-year-old, neutered male Persian cat, living
in an apartment was presented with urethral
obstruction. The cat was fed a commercial
dry cat food. The owner reported a 4-day history of in-
appetence, reduced water intake, dysuria, stranguria
and constipation and generalised weakness. On phys-
ical examination, its bladder was enlarged and painful
and the cat appeared depressed. Blood samples were
taken for routine laboratory evaluation. The complete
blood count revealed mild leukocytosis (20.5 103/ml,
reference interval (RI) 3.8e19 103/ml) with neutro-
philia (18,655/ml, RI 1290e15,950/ml) and all red
blood cell parameters were within reference range. Se-
rum biochemical analysis revealed severe azotaemia
(blood urea nitrogen, >300 mg/dl, RI 10e30 mg/dl;
creatinine >10 mg/dl, RI 0.8e2.0 mg/dl) and hyper-
kalaemia (potassium 9.6 mmol/l, RI 3.5e5.1 mmol/l).
Tests for feline leukaemia virus and feline immunode-
ficiency virus were negative (Snap Combo FeLV Ag/
FIV Ab Test Kit, Idexx Labs). The cat was treated
with diazepam (Diazepam; Intervet, 0.2 mg/kg IV)
and butorphanol (Torbugesic, Fort Dodge) at the37; Fax: þ351213652897.
 2010 ISFM adosage of 0.4 mg/kg and a sterile catheter was passed
through the urethra to the bladder, and then sutured
to the perineal skin. Haemorrhagic urine was re-
moved and analysed (see Table 1). Urinalysis revealed
pH 7.0 and the absence of crystalluria. The cat was
treated with intravenous physiological saline solution
0.9% to resolve the post-renal uraemia and hyperka-
laemia, ranitidine (Zantac; GlaxoSmithKline, 2 mg/
kg q12h IV) to reduce gastric acidity, and butorphanol
(0.4 mg/kg q8h IM) ensured analgesia. On day 3, the
urethral catheter was removed and the cat was seen to
urinate on its own. Haematology and serum biochem-
istry parameters were within reference ranges. After
catheterisation, an antimicrobial treatment course of
amoxicillin combined with clavulanic acid (Synulox;
Pfizer) at the dose of 12.5 mg/kg body weight, twice
daily, for 1 week was instituted. The cat was dis-
charged from the hospital with feline Urinary So
diet. On day 15 the cat was re-evaluated for persistent
haematuria, pollakiuria and stranguria due to a partial
urethral obstruction. The urinalysis was compatible
with inflammation in the absence of bacterial infection
(Table 1). Abdominal ultrasound examination de-
tected acoustic shadowing in the bladder consistent
with cellular debris, but no calculi, mass, thickeningnd AAFP. Published by Elsevier Ltd. All rights reserved.



































1037 1035 1015 1010 1030 1035 1020
pH (6e7) 7 7 7.5 8 6 7 6.5
Protein (0 to trace)
mg/dl
300 >2000 300 Low Negative 300 Negative
Glucose (negative) Negative Negative Negative Negative Negative Negative Negative
Bilirubin (negative) Negative Negative Negative Negative Negative Negative Negative
RBC/HPF (<5) >300 40e50 >300 rare 0e1 >300 1e2
WBC/HPF (<5) 0e1 0e1 8e10 0 1e2 2 0e1
Crystals (none) None None None None None None None
Epithelial cells
(occasional)
Rare Rare Occasional Occasional Rare Rare Rare
Bacteria (none if
cystocentesis used)
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804 C Pomba et alor mineralisation of the wall was observed. The left
kidney had normal form, size and echogenicity. The
right kidney had a cystic cortical lesion. The prescrip-
tion diet was maintained and flavoxate hydrochloride
was prescribed (50 mg PO q 12h) for urethral spasm
control. On day 23 a second complete urethral ob-
struction occurred, this time with a urinalysis compat-
ible with lower urinary tract infection (LUTI). Urine
culture was performed with a sample obtained by
cystocentesis. A mixed LUTI was found caused by
Staphylococcus pseudintermedius (>105 CFU/ml) and
Enterococcus faecalis (>105 CFU/ml) isolates. Antimi-
crobial susceptibility testing was performed using
the microbroth dilution method (DADE Behring Mi-
croscan PM21, USA), and interpreted according to
CLSI guidelines M31-A3 and M100-S171,2 (Table 2).
Discrimination between S pseudintermedius and Staph-
ylococcus intermedius was undertaken by pta polymer-
ase chain reaction-restriction fragment length
polymorphism analysis.3 Methicillin resistance in S
pseudintermedius was confirmed by polymerase chain
reaction detection of mecA (http://www.crl-ar.eu).
The methicillin-resistant S. pseudintermedius (MRSP)
harbored a SCCmec V cassette using MPCR1 and
MPCR2 described by Kondo et al,4 was Panton-Valen-
tine leukocidin (PVL) negative,5 and had spa type t06
(repeat sequence r01r02r03r03r06r05).6
Possible therapeutic options were based on the fol-
lowing principles: (i) both strains had to be suscepti-
ble to the antimicrobial agent; (ii) the agent had to
have good pharmacodynamic and pharmacokinetic
characteristics for use in LUTI; (iii) the antimicrobial
agent could not be one of the critically important an-
timicrobials for human medicine.7 Nitrofurantoin
was the only antimicrobial to fit all three criteria
(Table 2), and was prescribed at 4 mg/kg, q 8h, for
60 days (one quarter of the content of a 100 mg cap-
sule was administrated PO after dilution in 5 ml of
water with a syringe). The motivated owners of the
cat were a veterinary student and her mother. This en-
sured compliance. There were clear signs of clinical
improvement after 5 days and further urine samples
collected on days 5, 20, 25 and 60 after commencing
nitrofurantoin treatment were culture negative (Table 1).
However, on day 51 after the first episode of ure-
thral obstruction, a third episode of total obstruction
occurred (Table 1), and was not related to the
LUTI but probably due to the underlying presence
of a feline idiopathic cystitis obstructive form. This
required a perineal urethrostomy to alleviate the
obstruction.
Obstructive idiopathic cystitis (OIC) constitutes
a common medical problem of the lower urinary tract
in male cats and Persian cats appear to be predis-
posed.8,9 Urethral obstruction in cats may be present
with a concurrent urinary tract infection at the time
of obstruction relief.9 Risk factors for the occurrence
of a LUTI secondary to OIC remain to be elucidated.
In a retrospective caseecontrol study at three veteri-
nary referral hospitals, significant risk factors for theacquisition of a methicillin-resistant Staphylococcus
aureus infection compared to a methicillin-susceptible
S aureus infection was the presence of a urinary cath-
eter or co-infection.10 The third consecutive urethral
obstruction in our cat was associated with the pres-
ence of a mixed LUTI with a multi-drug resistant
MRSP. In our case, repeated bladder over-distension
and urinary catheterisation may have predisposed to
LUTI. The lack of a closed collection system at the
time of the urinary catheterisation and the use of anti-
microbial therapy during and after the first catheter-
isation procedure could have been contributing risk
factors for the LUTI. Antimicrobials and their selective
pressure have already been implicated in companion
animal MRSP infection or colonisation.11 The system-
atic use of sterile closed collection systems attached to
urethral catheters may overcome the occurrence of
a LUTI secondary to OIC and result in antimicrobial
prudent usage.
The recent clonal spread of MRSP in Europe is
largely due to the emergence of a single clone (t02,
ST71, SCCmec IIeIII).6,12 spa type t06 and SCCmec V
identical to those found in our MRSP, are associated
with an MRSP clone currently circulating in North
America (t06, ST68, SCCmec V).6,13 In addition to b-
lactam resistance, resistance in this isolate was ob-
served to five antimicrobial classes; fluoroquinolones,
lincosamides, macrolides, aminoglycosides and tri-
methoprim/sulfamethoxazole. Susceptibility was ob-
served to tetracycline and chloramphenicol. This
susceptibility pattern is also observed in the ST68
MRSP USA clone but not in the European one.14 The
MRSP causing LUTI in our patient is related to the
ST68 clone which is a common cause of LUTI and
pyoderma in the USA.
The E. faecalis also involved in the LUTI was ampi-
cillin susceptible and exhibited low-level gentamicin
resistance which is common in Portugal and in other
European countries.15,16 Therapeutic problems associ-
ated with enterococcal infections are often the result of
intrinsic resistance of this genus towards cephalospo-
rins, penicillinase-resistant penicillins, polymyxines,
low concentrations of aminoglycosides, clindamycin,
fluoroquinolones, streptogramines (E. faecalis) and
trimethoprim/sulfamethoxazole.
This case report describes for the first time a co-infec-
tion with a multi-drug resistant MRSP and E. faecalis in
a feline LUTI with pre-existing and recurrent urethral
obstruction. In Switzerland, multi-drug resistant
MRSP were previously found as a single causative
pathogen in three cats with urinary tract infection.17
The multi-resistance profile of MRSP strains spreading
in Europe and North America typically includes resis-
tance to all oral antimicrobials routinely used for treat-
ment of infections in small animal medicine. In the
present case report, therapeutic choices were even fur-
ther narrowed by the co-infection. Nitrofurantoin us-
age is not authorised in animals. However, the
rational for its use was the avoidance of using one of
the critically important antimicrobials in human
Table 2. In vitro activity of 28 selected antimicrobial agents tested against uropathogenic bacterial strains and possible therapeutic options.
Antimicrobial agent Uropathogenic bacterial strains
Methicillin-resistant Staphylococcus







Clinical breakpoints Clinical breakpoints MIC interpretation Options for
UTI treatment
Susceptible Resistant Susceptible Resistant
Amoxicillin-clavulanic acid 4/2 4/2 8/4 e NA NA R No
Ampicillin >8 0.25 0.5 <0.25 8 16 R No
Azithromycin >4 2 8 e NA NA R NoA
Cefotaxime <0.5 8 64 e NA NA R No
Chloramphenicol 8 8 32 8 8 32 S NoA
Ciprofloxacin >2 1 4 >2 1 4 R No
Clindamycin >2 0.5 4 e NA NA R NoA
Erythromycin >4 0.5 8 >4 0.5 8 R No
Fosfomycin <32 32 >32 e NA NA S NoB
Fusidic acid <2 2 32 e NA NA S NoB
Gatifloxacin 4 2 8 e NA NA I NoB
Gentamicin >8 4 16 e NA NA R No
Gentamicin high level e NA NA <500 <500 500 S NA
Levofloxacin 4 2 8 >4 2 8 R NoB
Linezolid 2 4 >4 <1 2 8 S NoB
Moxifloxacin 0.5 0.5 2 >2 1 2 R NoB
Mupirocin <4 4 256 e NA NA S NA
Netilmicin 8 8 32 e NA NA S NoB
Nitrofurantoin <32 32 128 <32 32 128 S Yes
Oxacillin* >4 0.25 0.25 e NA NA R No
Penicillin >8 0.12 0.25 2 8 16 R No
Quinupristin-dalfopristin <0.5 1 4 >2 1 4 R NoB
Rifampin <0.5 1 4 2 1 4 I NoB
Streptomycin high level e NA NA <1000 <1000 1000 S NoA
Teicoplanin <1 8 32 <1 8 32 S NoB
Tetracycline <2 4 16 >8 4 16 R No
Trimethoprim/sulfamethoxazole >2/38 2/38 4/76 e NA NA R No
Vancomycin 2 2 16 2 4 32 S NoB
NA¼ not applicable; No¼ therapy not possible due to antimicrobial resistance; NoA¼ therapy not applicable due to pharmacodynamic and pharmacokinetic
antimicrobial agent characteristics; NoB¼ critically important antimicrobial agents for humans as categorised by the Joint FAO/WHO/OIE Expert Meeting on
Critically Important Antimicrobials Report.5 Clinical breakpoint categorisation: S¼ susceptible bacterial isolate; I¼ intermediate bacterial isolate; R¼ resistant
bacterial isolate. MIC¼minimum inhibitory concentration.











































806 C Pomba et almedicine, eg, vancomycin. InfectionswithMRSP repre-
sent a real therapeutic challenge. The increased pres-
sure to use last resort antimicrobials that are saved for
the treatment of serious human infections raises impor-
tant ethical questions that demand revision of regula-
tory and preventive measures to control this
important animal health problem.Acknowledgments
This work was supported by the Interdisciplinary
Centre of Research in Animal Health from Fundac¸a˜o
para a Cieˆncia e a Tecnologia (FCT), Portugal. We are
grateful to our colleagues at the Veterinary Teaching
Hospital of the Faculty of Veterinary Medicine, Tech-
nical University of Lisbon.References
1. Clinical and Laboratory Standards Institute. Perfor-
mance standards for antimicrobial disk and dilution sus-
ceptibility tests for bacteria isolated from animals;
approved standard. Document M31-A3. 3rd edn. Wayne,
PA: CLSI, 2008.
2. Clinical and Laboratory Standards Institute. Perfor-
mance standards for antimicrobial susceptibility testing;
17th informational supplement. CLSI document M100-
S17. Wayne, Pennsylvania, USA: Clinical and Laboratory
Standards Institute, 2007.
3. Bannoehr J, Franco A, Iurescia M, Battisti A, Fitzgerald
JR. Molecular diagnostic identification of Staphylococcus
pseudintermedius. J Clin Microbiol 2009; 47: 469e71.
4. Kondo Y, Ito T, Ma XX, et al. Combination of multiplex
PCRs for staphylococcal cassette chromosome mec type
assignment: rapid identification system for mec, ccr,
and major differences in Junkyard regions. Antimicrob
Agents Chemother 2007; 51: 264e74.
5. Lina G, Pie´mont Y, Godail-Gamot F, et al. Involvement of
Panton-Valentine leukocidin e producing Staphylococcus
aureus in primary skin infections and pneumonia. Clin
Infect Dis 1999; 29: 1128e32.
6. Moodley A, Stegger M, Nouri L, Zakour B, Ross Fitzger-
ald J, Guardabassi L. Tandem repeat sequence analysis
of staphylococcal protein A (spa) gene in methicillin-re-
sistant Staphylococcus pseudintermedius. Vet Microbiol
2009; 135: 320e6.
7. FAO/OIE/WHO, 2008. Joint FAO/WHO/OIE expert
meeting on critically important antimicrobials, FAO,
Rome, Italy, 26e30 November 2007. Available at http://
www.fao.org/ag/agn/agns/files/Prepub_Report_CIA.
pdf.8. Gunn-Moore DA. Feline lower urinary tract disease.
J Feline Med Surg 2003; 5: 133e8.
9. Eggertsdo´ttir A, Lund HS, Krontveit R, Sørum H. Bacte-
riuria in cats with feline lower urinary tract disease:
a clinical study of 134 cases in Norway. J Feline Med
Surg 2007; 9: 458e65.
10. Faires M, Weese JS. Risk factors associated with methicil-
lin-resistant Staphylococcus aureus infections in dogs and
cats. Proceedings of the American Society for Micro-
biology meeting on antimicrobial resistance in zoonotic
bacteria and foodborne pathogens, Copenhagen, Den-
mark 2008; S8: 3.
11. Sasaki T, Kikuchi K, Tanaka Y, et al. Methicillin-resistant
Staphylococcus pseudintermedius in a veterinary teaching
hospital. J Clin Microbiol 2007; 2007(45): 1118e25.
12. Kadlec K, Schwarz S, Moodley A, et al. Clonal spread of
methicillin-resistant Staphylococus pseudintermedius. Pro-
ceedings of the American Society for Microbiology meet-
ing on methicillin-resistant staphylococci in animals;
veterinary and public health implications, London, UK
2009; S1: 1.
13. Black CC, Solymana SM, Eberleina LC, Bemisa DA,
Woronb AM, Kania SA. Identification of a predominant
multilocus sequence type, pulsed-field gel electropho-
resis cluster, and novel staphylococcal chromosomal
cassette in clinical isolates of mecA-containing, methi-
cillin-resistant Staphylococcus pseudintermedius. Vet
Microbiol 2009; 139: 333e8.
14. Andersson U, Finn M, Kadlec K, et al. Methicillin-resis-
tant Staphylococus pseudintermedius: an emerging com-
panion animal health problem. Proceedings of the
American Society for Microbiology Conference on Meth-
icillin-resistant Staphylococci in Animals: Veterinary and
Public Health Implications, London, UK 2009; S1: 2.
15. Damborg P, Sørensen AH, Guardabassi L. Monitor-
ing of antimicrobial resistance in healthy dogs: first
report of canine ampicillin-resistant Enterococcus
faecium clonal complex 17. Vet Microbiol 2008; 132:
190e6.
16. Delgado M, Neto I, Duarte-Correia JH, Pomba C. An-
timicrobial resistance and evaluation of susceptibility
testing among pathogenic enterococci isolated from
dogs and cats. Int J Antimicrob Agents 2007; 30:
98e100.
17. Wettstein K, Dsecloux S, Rossano A, Perreten V. Emer-
gence of methicillin-resistant Staphylococcus pseudinter-
medius in Switzerland: three cases of urinary tract
infections in cats. Schweiz Arch Tierheilkd 2008; 150:
339e43.
18. Bemis DA, Jones RD, Frank LA, Kania SA. Evalua-
tion of susceptibility test breakpoints used to predict
mecA-mediated resistance in Staphylococcus pseudin-
termedius isolated from dogs. J Vet Diagn Invest
2009; 21: 53e8.Available online at www.sciencedirect.com
